COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature

Autor: Claudia Ferrara, Rossella Di Trolio, Simona Iaccarino, Zisis Kozlakidis, Mario Polverino, Gianluca Ragone, Giuseppina Busto, Luciana Buonerba, Concetta Ingenito, Emilio Leo, Ferdinando De Falco, Beatrice Savastano, Annamaria Libroia, Giuseppe Di Lorenzo, Concetta dello Ioio
Rok vydání: 2020
Předmět:
0301 basic medicine
Ruxolitinib
AIFA
Italian Medicines Agency (Agenzia Italiana del Farmaco)
COVID-19
corona virus disease
DPP4
Dipeptidyl peptidase 4
medicine.medical_treatment
Disease
Antiviral therapy
Targeted therapy
chemistry.chemical_compound
ARSI
androgen receptor signaling inhibitors
0302 clinical medicine
DMARDs
disease-modifying antirheumatic drugs
Coronavirus disease SARS-CoV-2 (COVID-19)
media_common
Cancer
Hematology
Management
Oncology
030220 oncology & carcinogenesis
CYP
cytochrome P450
Coronavirus Infections
medicine.drug
Drug
medicine.medical_specialty
media_common.quotation_subject
IL6
interleukin 6
Pneumonia
Viral
Context (language use)
Antineoplastic Agents
Ace2
angiotensin-converting enzyme 2
HIV-1
human immunodeficiency virus
Article
03 medical and health sciences
Betacoronavirus
Tocilizumab
medicine
Drug-interactions
Humans
Intensive care medicine
Pandemics
business.industry
SARS-CoV-2
COVID-19
medicine.disease
COVID-19 Drug Treatment
Clinical trial
CPI
checkpoint inhibitors
030104 developmental biology
chemistry
business
Zdroj: Critical Reviews in Oncology/Hematology
ISSN: 1879-0461
Popis: Background It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19). Methods We conducted a literature review on https://www.ncbi.nlm.nih.gov/pubmed/ , https://scholar.google.com , www.arxiv.org , www.biorxiv.org , of all articles published using the keywords COVID-19 therapy or treatment and cancer until May 2, 2020. A total of 205 articles were identified and 53 were included in this review. Results We describe the ongoing COVID-19 therapies that should be known by oncologists and highlight the potential interactions with antineoplastic drugs, commonly used in clinical practice. The main drug interactions were found with tocilizumab, ruxolitinib and colchicine. Conclusions. The literature provides an inconclusive picture on potential preferred treatments for COVID-19 and their interactions with antineoplastic agents. Future clinical trials are needed to better understand the interactions between different drugs in the context of COVID-19 pandemic.
Databáze: OpenAIRE
Externí odkaz: